Ajay Kirtane
Interventional Cardiology · New York, NYNPI 1780651497
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (57.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 78.3% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $355,224, more than ten times the $13,424 reported in 2019. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $1157.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$362K
- Medtronic$51K
- Merck$13K
- Abbott$9K
- Biotronik Inc.$9K
- Janssen Research & Development, LLC$3K
- plus $14K from 25 others
Across 141 payments — averaging $9710.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$504K
- Abbott$496K
- Recor Medical Inc$115K
- Philips North America LLC$64K
- Shockwave Medical, Inc$54K
- Boston Scientific$45K
- plus $91K from 3 others
What the payments were for
- Consulting fees$90,37920%
- Speaking & faculty fees$67,01215%
- Grants$6,0551%
- Travel & lodging$14,2553%
- Food & beverage$20,8845%
- Other$263,09057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 124 | $361,633 |
| Medtronic(2 entities) | 108 | $51,175 |
| Merck | 12 | $13,298 |
| Abbott | 20 | $9,237 |
| Biotronik Inc. | 16 | $8,755 |
| Janssen Research & Development, LLC | 3 | $3,360 |
| Shockwave Medical, Inc | 3 | $2,488 |
| Idorsia Pharmaceuticals US Inc | 8 | $2,460 |
| Recor Medical Inc | 6 | $1,810 |
| Cardiovascular Systems Inc. | 10 | $1,313 |
| Cathworks, Inc. | 7 | $1,083 |
| Philips North America LLC | 4 | $1,008 |
| Edwards Lifesciences | 4 | $532 |
| Abiomed | 6 | $490 |
| Teleflex LLC | 3 | $470 |
| Novartis | 21 | $361 |
| Amgen | 9 | $312 |
| Neovasc Medical Inc | 3 | $305 |
| Acist Medical Systems, Inc. | 2 | $299 |
| Siemens Medical Solutions USA, Inc. | 3 | $219 |
| Cordis US CORP. | 1 | $214 |
| Boehringer Ingelheim | 9 | $163 |
| Heartflow, Inc. | 6 | $136 |
| Regeneron | 1 | $130 |
| Asahi Intecc USA, Inc. | 3 | $111 |
| W. L. Gore & Associates, Inc. | 1 | $89 |
| Angiodynamics, Inc. | 1 | $87 |
| Pfizer | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| Bridgebio Pharma, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$264,481
- GENERAL VASCULAR ACCESS$43,609
- CLINICAL TRIAL PRODUCT$10,875
- Resolute$10,224
- SYMPLICITY G3$7,950
- ONYX FRONTIER$6,946
- General Therapies IC$6,000
- Orsiro Mission$5,507
- NHancer Rx$5,332
- ReCross$5,332
- TrapIT$5,332
- RESOLUTE ONYX$4,489
- OPTIS$3,357
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,488
- ABSOLUTE PRO$2,400
- APROCITENTAN$2,262
- GENERAL - STENTS$2,188
- PARADISE RENAL DENERVATION SYSTEM$1,465
- GENERAL BALLOONS$1,250
- FFRangio$991
How this compares
$461,675 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 34 | $414 |
| Ezetimibe | 13 | $289 |
| Metoprolol Succinate | 14 | $169 |
| ClopidogrelClopidogrel Bisulfate | 17 | $162 |
| Amlodipine Besylate | 18 | $95 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
- Jeffrey MosesNew York$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.